Glycolysis inhibition induces anti-tumor central memory CD8⁺T cell differentiation upon combination with microwave ablation therapy.

Abstract

Minimally invasive thermal therapy is a successful alternative treatment to surgery in solid tumors with high complete ablation rates, however, tumor recurrence remains a concern. Central memory CD8⁺ T cells (T_CM) play important roles in protection from chronic infection and cancer. Here we find, by single-cell RNA analysis of human breast cancer samples, that although the memory phenotype of peripheral CD8⁺ T cells increases slightly after microwave ablation (MWA), the metabolism of peripheral CD8⁺ T cells remains unfavorable for memory phenotype. In mouse models, glycolysis inhibition by 2-deoxy-D-glucose (2DG) in combination with MWA results in long-term anti-tumor effect via enhancing differentiation of tumor-specific CD44^hiCD62L⁺CD8⁺ T_CM cells. Enhancement of CD8⁺ T_CM cell differentiation determined by Stat-1, is dependent on the tumor-draining lymph nodes (TDLN) but takes place in peripheral blood, with metabolic remodeling of CD8⁺ T cells lasting the entire course of the the combination therapy. Importantly, in-vitro glycolysis inhibition in peripheral CD8⁺ T cells of patients with breast or liver tumors having been treated with MWA thrice leads to their differentiation into CD8⁺ T_CM cells. Our work thus offers a potential strategy to avoid tumor recurrence following MWA therapy and lays down the proof-of-principle for future clinical trials.